Entyvio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of conventional immunosuppressive therapies, rising incidence of inflammatory bowel disease, strong clinical outcomes for vedolizumab, gastroenterologist adoption of biologics, regulatory approvals for uc and cd.

The growth in the forecast period can be attributed to increasing global ibd prevalence, expansion into earlier treatment lines, improved diagnostic rates, growing biologic therapy access, long term disease management focus. Major trends in the forecast period include rising use of gut selective biologic therapies, growing adoption in moderate to severe ibd, increased preference for targeted integrin inhibition, expansion of long term maintenance therapy use, improved safety focus compared to systemic immunosuppressants.

The rising incidence of inflammatory bowel disease is expected to drive the growth of the Entyvio market in the coming years. Inflammatory bowel disease (IBD) comprises a group of chronic, relapsing inflammatory conditions affecting the gastrointestinal tract, caused by immune system dysregulation that leads to persistent inflammation and tissue damage. The increasing occurrence of IBD is linked to factors such as genetic susceptibility, environmental influences including dietary patterns and urbanization, lifestyle changes such as elevated stress levels, and disruptions in gut microbiota resulting from antibiotic use and reduced exposure to natural microbes. Entyvio helps treat inflammatory bowel disease by selectively targeting and blocking the alpha4beta7 integrin, thereby limiting the movement of inflammatory cells into the gut. For instance, in June 2024, according to the Centers for Disease Control and Prevention, a US-based non-profit organization, it is estimated that between 2.4 and 3.1 million people in the United States are living with inflammatory bowel disease. Therefore, the increasing prevalence of inflammatory bowel disease is driving the growth of the Entyvio market.

The increase in healthcare expenditure is expected to further propel the growth of the Entyvio market going forward. Healthcare expenditure refers to the total financial resources allocated to health-related goods and services to maintain or improve individual and population health. Rising healthcare spending is driven by factors such as the growing burden of chronic diseases, advancements in medical technology, an aging population requiring more complex care, higher costs of prescription medications and specialized treatments, and expanded access to healthcare services across developed and developing regions. Healthcare expenditure supports Entyvio by enabling access to advanced biologic therapies for patients with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis, while also providing funding for its research, development, distribution, and incorporation into clinical treatment guidelines, ultimately improving patient outcomes and healthcare system efficiency. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the United Kingdom increased by 5.6% between 2022 and 2023, compared with a growth rate of 0.9% in 2022. Total healthcare expenditure in the UK was approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is contributing to the growth of the Entyvio market.

Major companies operating in the Entyvio market are focusing on the development of maintenance therapies to improve the long-term management of inflammatory bowel disease. Maintenance therapies are ongoing treatments intended to sustain disease control, prevent progression, and reduce the risk of relapse after initial treatment goals have been achieved. These therapies aim to minimize complications and symptoms over time, supporting long-term disease stability and enhanced quality of life for patients. For instance, in April 2024, Takeda Pharmaceutical, a US-based pharmaceutical company, received approval from the Food and Drug Administration, a US federal agency, for subcutaneous administration of Entyvio as a maintenance therapy in adults with moderately to severely active Crohn’s disease following induction treatment with intravenous Entyvio. The subcutaneous formulation enables self-administration through a prefilled pen, offering greater convenience for patients managing their treatment at home after the induction phase. Clinical studies have demonstrated that Entyvio significantly improves symptoms and induces remission in patients with Crohn’s disease compared with placebo.

Major companies operating in the entyvio market are Takeda Pharmaceutical Company Limited.

North America was the largest region in the Entyvio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the entyvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the entyvio market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the entyvio market by increasing costs for imported monoclonal antibody inputs and infusion related consumables. These impacts are most visible in hospital and clinic based infusion centers across north america and europe. Higher tariffs have contributed to pricing pressure for biologic gastrointestinal therapies. However, they are also supporting regional biologic manufacturing investments. This enhances long term supply stability for ibd treatments.

The entyvio market research report is one of a series of new reports that provides entyvio market statistics, including entyvio industry global market size, regional shares, competitors with a entyvio market share, detailed entyvio market segments, market trends and opportunities, and any further data you may need to thrive in the entyvio industry. This entyvio market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Entyvio (vedolizumab) is a monoclonal antibody therapy that acts as an integrin receptor antagonist. It works by selectively blocking the migration of inflammatory white blood cells into the gastrointestinal tract, thereby reducing inflammation and helping to manage the symptoms associated with these conditions.

The primary routes of administration in the Entyvio market include subcutaneous injection and intravenous infusion. Subcutaneous administration of Entyvio (vedolizumab) allows patients to self-administer the medication at home. The treatment is utilized across different lines of therapy, including first-line and second-line treatment, and is indicated for conditions such as ulcerative colitis (UC) and Crohn’s disease (CD). These therapies are used by a range of end users, including hospitals, clinics, ambulatory care centers, and home care settings.

The entyvio market consists of sales of induction therapy and maintenance therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.